Mojun Zhu, MD, discusses key findings from the phase 3 TOPAZ-1 trial in patients with biliary tract cancer.
Mojun Zhu, MD, oncologist, Mayo Clinic, discusses key findings from the phase 3 TOPAZ-1 trial (NCT03875235) in patients with biliary tract cancer.
The TOPAZ-1 trial evaluated the addition of durvalumab (Imfinzi) to standard-of-care cisplatin plus gemcitabine in advanced biliary tract cancer, Zhu says. Moreover, the treatment was not associated with immune-related adverse events (AEs) in this patient population, Zhu explains.
Survival curves for durvalumab plus gemcitabine and cisplatin are consistent with previous data of evaluating with immunotherapy in this patient population, Zhu notes. After 6 months of treatment, patients receiving the chemoimmunotherapy regimen experienced significant clinical benefit compared with placebo, Zhu continues.
These data suggest that certain subgroups may derive increased long-term benefit from the addition of immune checkpoint inhibitors to first-line treatment and support this regimen as a potential standard of care in biliary tract cancer, Zhu concludes.